We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Eurofins Technologies

  Gold Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test k... read more Featured Products: More products

Download Mobile App





Eurofins Launches New Multiplex PCR Assay for Rapid Detection of B.1.617 Kappa SARS-CoV-2 Variant

By LabMedica International staff writers
Posted on 04 Jun 2021
Print article
Image: GSD NovaType III SARS-CoV-2 RT-PCR assay (Photo courtesy of Eurofins Technologies)
Image: GSD NovaType III SARS-CoV-2 RT-PCR assay (Photo courtesy of Eurofins Technologies)
Eurofins Technologies (Ebersberg, Germany) has launched its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).

The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant. These mutations have been associated with reports of potential decreased efficacy of certain vaccines and an increase in the transmissibility of the virus.

GSD NovaType III SARS-CoV-2 is the latest addition to the GSD NovaType product line, a continuously updated panel of single and multiplex assays for the screening and detection of emerging Variants of Concern (VOC) and of Interest (VOI) on positive samples. These assays may play an important role in the fight against COVID-19 by enabling the rapid identification of new variants that may endanger the success of global vaccination campaigns and the implementation of enhanced isolation, testing and vaccination measures in affected areas. GSD NovaType III SARS-CoV-2 will be available as a research-use-only kit by the June 9. A CE marked version is expected by the second half of June.



New
Gold Supplier
SARS-CoV-2 IgG ELISA Kit
NovaLisa SARS-CoV-2 IgG
New
Gold Supplier
Nucleic Acid Extractor
MGISP-NE384
New
D-Dimer ELISA Kit
D-Dimer AccuBind ELISA Kit
New
Sepsis Detection Test
SeptiCyte RAPID

Print article
BIOHIT  Healthcare OY

Channels

Clinical Chem.

view channel
Image: Blood test for  plasma aldosterone concentration was used to screen For hyperaldosteronism in hypertensive men (Photo courtesy of  VisitHealth Ltd)

Urinary Sodium/Potassium Ratio Screens for Hyperaldosteronism in Hypertensive Men

Among individuals with hypertension, the prevalence of secondary hypertension has been reported to be around 10%. More than half of individuals with secondary hypertension have associated hyperaldosteronism.... Read more

Industry

view channel
Illustration

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.